Stocktoria
Mobile-health Network Solutions MNDR
Mobile-health Network Solutions (MNDR) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $7.6M at a -44.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 2.62 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MNDR | Mobile-health Network Solutions | 1/9 | — | — | -45.3% |
| AITX | Artificial Intelligence Technology Solutions Inc. | 4/9 | — | — | — |
| RYET | Ruanyun Edai Technology Inc. | 1/9 | -6.58 | — | — |
| IFBD | Infobird Co., Ltd | 2/9 | — | — | — |
| HKIT | HiTek Global Inc. | 4/9 | 11.81 | 14.2 | — |
| MYSZ | My Size, Inc. | 2/9 | — | — | — |
| NTCL | NetClass Technology Inc | 1/9 | -6.52 | — | -2.9% |
About Mobile-health Network Solutions
Mobile-health Network Solutions, an investment holding company, provides telehealth solutions primarily in Singapore. The company operates in two segments: Telemedicine and Other Services and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website, as well as Internet search engines. The company also provides a suite of medical-related and other services, including teleconsultations and health check-up services, vaccinations, skin and aesthetics services, and other services. In addition, it offers healthcare and wellness products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics through MaNaPharma platform; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical services. Additionally, it offers health supplements, skincare, nutrition products and medical devices wellness, personal care; health screening packages; and online services such as medical screenings and procedures, such as serology and swab tests. The company was founded in 2009 and is headquartered in Singapore.
FAQ
Is MNDR financially healthy?
Mobile-health Network Solutions's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does MNDR pay a dividend?
No, Mobile-health Network Solutions does not currently pay a dividend.
How profitable is MNDR?
In FY2025, Mobile-health Network Solutions had a net margin of -44.3% and a return on equity of -129.3%.
Is MNDR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Mobile-health Network Solutions: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.